Fig. 3: F8 and C9 antibody fragments localize to solid tumors in vivo.
From: Tumor-agnostic cancer therapy using antibodies targeting oncofetal chondroitin sulfate
a In Vivo Imaging system (IVIS) localization of 50 μg Alexa750-labeled antibody (SpyC2, B3, F4, F11, F3, F8, and C9) injected in 4T1 allografted mice with two mice per construct. Tumor area is encircled in red. b IVIS localization of C9 and F8 scFv2 fused to albumin binding domain (ABD) in Karpas299 lymphoma xenografted mice after injection (0 h), 24 h, and 48 h after injection. c Ex vivo IVIS signals from the mice in panel b. 48 h after injection of ABD-control, ABD-C9, ABD-F8. d IVIS localization in patient-derived xenograft (PDX) model of neuroendocrine prostate cancer in male mice as described in b in vivo, and e ex vivo of mice from (d). 48 h, with radiant efficiency measured for each organ. f Ex vivo scanning in MiaPaca2 pancreatic xenograft model 24 h after injection of indicated proteins. Source data are provided as a Source data file.
